



(51) International Patent Classification:

C07H 19/06 (2006.01) **C07H 1/00** (2006.01)
C07H 19/10 (2006.01) **C07H 1/02** (2006.01)
C07H 19/11 (2006.01) **C07H 1/04** (2006.01)
C07H 19/16 (2006.01) **A61K 31/7068** (2006.01)
C07H 19/167 (2006.01) **A61K 31/7072** (2006.01)
C07H 19/173 (2006.01) **A61K 31/7076** (2006.01)
C07H 19/20 (2006.01) **A61K 31/708** (2006.01)
C07H 19/207 (2006.01) **A61K 31/14** (2006.01)
C07H 19/213 (2006.01) **A61K 31/16** (2006.01)

(21) International Application Number:

PCT/US2014/059849

(22) International Filing Date:

9 October 2014 (09.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/890,136 11 October 2013 (11.10.2013) US
 62/016,288 24 June 2014 (24.06.2014) US

(71) Applicant: **ALIOS BIOPHARMA, INC.** [US/US]; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

(72) Inventors: **BEIGELMAN, Leonid**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **WANG, Guangyi**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **SMITH, David, Bernard**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **PRHAVC, Marija**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US). **JEKLE, Christian, Andreas**; 260 E. Grand Avenue, 2nd Floor,

South San Francisco, CA 94080 (US). **DEVAL, Jerome**; 260 E. Grand Avenue, 2nd Floor, South San Francisco, CA 94080 (US).

(74) Agent: **MILLER, Kimberly, J.**; Knobbe, Martens, Olson & Bear, LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Figure 9: Compounds of Formula (I)



(57) Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.

Published:

— *with international search report (Art. 21(3))*